Press Releases

Nivalis Therapeutics to Present at the JMP Securities Life Sciences Conference

BOULDER, Colo., June 15, 2016 (GLOBE NEWSWIRE) -- Nivalis Therapeutics, Inc. (NASDAQ:NVLS), a clinical stage pharmaceutical company focused on treating people with cystic fibrosis (“CF”), today announced that Chief Executive Officer, Jon Congleton will present a corporate overview at the JMP Securities Life Sciences Conference.

Details of the presentations are as follows:

JMP Securities Life Sciences Conference
Date: Wednesday, June 22nd
Location: The St. Regis New York, New York
Presentation Time: 12:30 PM EDT

Individuals may access a live webcast of the conference presentations on the Nivalis website at under "IR Calendar" in the "News / Events" section.  A replay of the webcast will be available on this site for 90 days following the live event.

About Nivalis Therapeutics, Inc.
Nivalis Therapeutics, Inc. ( is a clinical-stage pharmaceutical company committed to the discovery, development and commercialization of therapeutics for people with CF. In addition to developing innovative solutions intended to extend and improve the lives of people with CF, Nivalis plans to utilize its proprietary S-nitrosoglutathione reductase (GSNOR) inhibitor portfolio to develop therapeutics for other diseases.


Investor Relations
John Graziano

Media Relations
Lindsay Rocco

Primary Logo

Source: Nivalis Therapeutics, Inc.


Nivalis Therapeutics is not responsible for the content on linked websites.

The document you requested is located on the Journal of Applied Physiology website. A subscription is required to view the document.